KLRC1 and breast carcinoma: Frazao A showed that NK cells from tumor-draining lymph nodes expressed high NKG2A and checkpoint programmed cell death protein 1 (PD-1), which supported their potential as targets for immunotherapy using anti-NKG2A and/or anti-PD-1 in breast cancer (65).